Effects of Psilocybin in Obsessive Compulsive Disorder (NCT05546658)

🧪 Interventions in This Study

• Psilocybin (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Have given written informed consent
2. Currently meet criteria for a DSM-5 diagnosis of OCD and report a history of OCD for at least 1 year prior to screening
3. Have a Y-BOCS score of 18 or more
4. Have at least one prior attempt at treatment, either ERP or pharmacotherapy
5. No antidepressant medications for approximately five half-lives prior to acceptance in treatment phase of study
6. Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control must agree to practice an effective means of birth control throughout the duration of the study
7. Be judged by study team clinicians to be at low risk for suicidality
8. Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study
9. Be otherwise medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests (CBC, CMP, urine beta-HCG, urine toxicology screen)
10. Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days
11. Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of each drug administration. The exceptions are caffeine and nicotine
12. Agree not to take any PRN medications on the mornings of drug sessions

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Johns Hopkins University School of Medicine — Baltimore, Maryland

📞 Contact the Study Coordinator

Phone: (855) 694-6725

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Obsessive-Compulsive Disorder

• Towards Remission and Full Recovery From Obsessive-compulsive Disorder — Montreal, Quebec
• Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD — New Haven, Connecticut
• Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD — Toronto, Ontario
• Study of Dextromethorphan in OCD and Related Disorders — Stanford, California
• Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) — Stanford, California

Explore by condition: All Obsessive-Compulsive Disorder clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.